 Connection
David Fleischer to Administration, Oral
This is a "connection" page, showing publications David Fleischer has written about Administration, Oral.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.532 |
|
|
|
-
B?gin P, Bird JA, Spergel JM, Campbell DE, Green TD, Bee KJ, Lambert R, Sampson HA, Fleischer DM. Reduction in peanut reaction severity during oral challenge after 12 months of epicutaneous immunotherapy. Allergy. 2021 12; 76(12):3835-3838.
Score: 0.168
-
Otsu K, Fleischer DM. Therapeutics in food allergy: the current state of the art. Curr Allergy Asthma Rep. 2012 Feb; 12(1):48-54.
Score: 0.086
-
Byrne AM, Malka-Rais J, Burks AW, Fleischer DM. How do we know when peanut and tree nut allergy have resolved, and how do we keep it resolved? Clin Exp Allergy. 2010 Sep; 40(9):1303-11.
Score: 0.078
-
Chua GT, Greenhawt M, Shaker M, Soller L, Abrams EM, Cameron SB, Cook VE, Erdle SC, Fleischer DM, Mak R, Vander Leek TK, Chan ES. The Case for Prompt Salvage Infant Peanut Oral Immunotherapy Following Failed Primary Prevention. J Allergy Clin Immunol Pract. 2022 10; 10(10):2561-2569.
Score: 0.044
-
Pongracic JA, Gagnon R, Sussman G, Siri D, Oriel RC, Brown-Whitehorn TF, Green TD, Campbell DE, Anvari S, Berger WE, Bird JA, Chan ES, Cheema A, Chinthrajah RS, Chong HJ, Dowling PJ, Fineman SM, Fleischer DM, Gonzalez-Reyes E, Kim EH, Lanser BJ, MacGinnitie A, Mehta H, Petroni D, Rupp N, Schneider LC, Scurlock AM, Sher LD, Shreffler WG, Sindher SB, Stillerman A, Wood R, Yang WH, Bois T, Sampson HA, B?gin P. Safety of Epicutaneous Immunotherapy in Peanut-Allergic Children: REALISE Randomized Clinical Trial Results. J Allergy Clin Immunol Pract. 2022 07; 10(7):1864-1873.e10.
Score: 0.043
-
Vickery BP, Vereda A, Casale TB, Beyer K, du Toit G, Hourihane JO, Jones SM, Shreffler WG, Marcantonio A, Zawadzki R, Sher L, Carr WW, Fineman S, Greos L, Rachid R, Ib??ez MD, Tilles S, Assa?ad AH, Nilsson C, Rupp N, Welch MJ, Sussman G, Chinthrajah S, Blumchen K, Sher E, Spergel JM, Leickly FE, Zielen S, Wang J, Sanders GM, Wood RA, Cheema A, Bindslev-Jensen C, Leonard S, Kachru R, Johnston DT, Hampel FC, Kim EH, Anagnostou A, Pongracic JA, Ben-Shoshan M, Sharma HP, Stillerman A, Windom HH, Yang WH, Muraro A, Zubeldia JM, Sharma V, Dorsey MJ, Chong HJ, Ohayon J, Bird JA, Carr TF, Siri D, Fern?ndez-Rivas M, Jeong DK, Fleischer DM, Lieberman JA, Dubois AEJ, Tsoumani M, Ciaccio CE, Portnoy JM, Mansfield LE, Fritz SB, Lanser BJ, Matz J, Oude Elberink HNG, Varshney P, Dilly SG, Adelman DC, Burks AW. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J Med. 2018 Nov 22; 379(21):1991-2001.
Score: 0.035
-
Bird JA, Groetch M, Allen KJ, Bock SA, Leonard S, Nowak-Wegrzyn AH, Sicherer S, Clark A, Fleischer DM, Venter C, Vickery B, Young MC. Conducting an Oral Food Challenge to Peanut in an Infant. J Allergy Clin Immunol Pract. 2017 Mar - Apr; 5(2):301-311.e1.
Score: 0.030
-
Klinnert MD, Silveira L, Harris R, Moore W, Atkins D, Fleischer DM, Menard-Katcher C, Aceves S, Spergel JM, Franciosi JP, Furuta GT. Health-related quality of life over time in children with eosinophilic esophagitis and their families. J Pediatr Gastroenterol Nutr. 2014 Sep; 59(3):308-16.
Score: 0.026
-
Burks AW, Jones SM, Wood RA, Fleischer DM, Sicherer SH, Lindblad RW, Stablein D, Henning AK, Vickery BP, Liu AH, Scurlock AM, Shreffler WG, Plaut M, Sampson HA. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med. 2012 Jul 19; 367(3):233-43.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|